NewAmsterdam Pharma (NASDAQ:NAMS) Given Average Rating of “Buy” by Brokerages

NewAmsterdam Pharma (NASDAQ:NAMS) has received a consensus recommendation of “Buy” from the six research firms that are presently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have covered the stock in the last year is $41.60.

Several research firms have issued reports on NAMS. Royal Bank of Canada restated an “outperform” rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday. Needham & Company LLC restated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Finally, Scotiabank upped their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a report on Wednesday, December 11th.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the sale, the insider now owns 11,778,760 shares of the company’s stock, valued at approximately $295,411,300.80. The trade was a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 446,730 shares of company stock valued at $11,438,695 in the last ninety days. 19.50% of the stock is currently owned by corporate insiders.

Institutional Trading of NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of NewAmsterdam Pharma by 1.6% during the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after purchasing an additional 1,399 shares during the period. Quarry LP increased its stake in NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after acquiring an additional 6,247 shares during the period. Barclays PLC raised its holdings in NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after acquiring an additional 7,199 shares in the last quarter. Bellevue Group AG bought a new stake in shares of NewAmsterdam Pharma during the 3rd quarter valued at $128,000. Finally, Sei Investments Co. grew its holdings in shares of NewAmsterdam Pharma by 49.1% during the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after purchasing an additional 8,087 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Trading Up 1.7 %

Shares of NASDAQ:NAMS opened at $23.60 on Monday. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29. The company has a 50-day simple moving average of $23.55 and a 200 day simple moving average of $19.93.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.